ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2061

Physician Variation in Documentation of Rheumatoid Arthritis Quality Measures and Evaluation of Relationship with Radiographic Progression

Sonali Desai1, Jinoos Yazdany2, Nancy A. Shadick3, Siri Lillegraven4, Chih-Chin Liu5, Michelle A. Frits6, Tabatha Norton7, Jonathan S. Coblyn8, Michael Weinblatt5 and Daniel H. Solomon9, 1Medicine/ Rheumatology, Boston, MA, 2Medicine, University of California, San Francisco, San Francisco, CA, 3Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 6Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 9Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: functional status, quality of care and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose: Documentation of quality measures (QMs) in rheumatoid arthritis (RA) has been proposed as a way to demonstrate quality of care, but data linking appropriate documentation to improved clinical outcomes are lacking.  We examined the variation in physician documentation of RA QMs on disease activity and functional status and the association with radiographic outcomes.

Methods: We studied a subset of 286 patients participating in a longitudinal RA cohort followed from 2003-2008 at an academic medical center with complete data on total sharp score (TSS) (2 hand x-rays approximately 2 years apart).  All clinical notes from 18 different rheumatologists during a 24-month period preceding the date of the second hand x-ray were examined for the presence or absence of the RA QMs on disease activity and functional status. Disease activity QM documentation was defined as mention of disease activity assessment in the medical record, with details categorizing disease activity into low, medium or high. Functional status QM documentation was defined as mention of how RA impacted activities of daily living. Change in TSS was defined as an annualized progression rate and dichotomized as progression (≥ 1U per year) or no progression (<1U per year). We examined: patient visits per MD per year; RA QM documentation as either disease activity, functional status or both; and mean % of visits with RA QM documentation. We compared the mean change in TSS across patients grouped by percentage of visits meeting a QM, i.e., none or some documentation of disease activity and functional status.

Results: The mean age of our patients was 57.0 (±14.0) years, 82.0% were female, mean disease duration was 10.4 (±10.9) years, baseline DAS28 score was 3.7 (±1.5) and 65.9% were either RF or CCP positive. 76.6% of patients were on a non-biologic and 31.5% were on a biologic DMARD. Radiographic progression of RA was reported in 27.0% of patients. There was at least one chart note with documentation of disease activity for 26.0% of patients and functional status for 75.0%, during the 24-month period. For the seven rheumatologists with at least 10 patients in the study, there was variation in the number of visits per patient per year and documentation of disease activity and functional status in chart notes (Table).  In unadjusted analyses, there was no relationship between performance on either disease activity (p=0.6) or functional status (p=0.5) and change in TSS.

Conclusion: Among this cohort of RA patients with established disease, overall documentation of RA QMs on disease activity and functional status was inconsistent across rheumatologists. We did not find an association between the % of visits with an RA QM documented and radiographic outcome over a 24-month follow-up period. 

Table. Differences in RA visits and QM documentation by rheumatologist

MD

Study sample patients

N (%)

Patient visits per year

mean (min-max)

Disease activity at least once

N (%)

Functional status at least once

N (% )

Both QMs at least once

N (%)

% of visit with QM

(mean)

N=7*

N=242

24-month follow-up

24-month follow-up

24-month follow-up

24-month follow-up

Disease activity

Functional status

A

50 (20.7)

8.6 (3-14)

4 (8)

27 (54)

1 (2)

1.6

22.0

B

20 (8.3)

9 (6-12)

0

12 (60)

0

0.0

11.0

C

28 (11.6)

8.9 (4-15)

9 (32.1)

18 (64.3)

3 (10.7)

8.8

19.2

D

10 (4.1)

6.9 (4-12)

3 (30)

4 (40)

1 (10)

11.3

11.2

E

10 (4.1)

9.4 (5-16)

3 (30)

7 (70)

1 (10)

5.0

18.3

F

21 (8.7)

8 (4-19)

3 (14.3)

21 (100)

1 (4.8)

2.5

46.8

G

103 (42.6)

7.8 (3-18)

42 (40.8)

90 (87.4)

22 (21.4)

8.5

53.7

* The 7 rheumatologists represented in this table contributed at least 10 patients to the study sample


Disclosure:

S. Desai,
None;

J. Yazdany,
None;

N. A. Shadick,

Amgen,

2,

Abbott Immunology Pharmaceuticals,

2,

Genentech and Biogen IDEC Inc.,

2,

Crescendo Bioscience,

2,

Medimmune,

2;

S. Lillegraven,

testtest,

2;

C. C. Liu,
None;

M. A. Frits,
None;

T. Norton,
None;

J. S. Coblyn,

CVS,

5;

M. Weinblatt,

MedImmune,

2,

Crescendo Bioscience,

2,

MedImmune,

5,

Crescendo Bioscience,

5;

D. H. Solomon,

Abbott Immunology Pharmaceuticals,

2,

Lilly,

2,

Corrona,

5,

Up to Date,

7.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physician-variation-in-documentation-of-rheumatoid-arthritis-quality-measures-and-evaluation-of-relationship-with-radiographic-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology